The bet with a date on it
The most concrete financial event in this cancer-drug story is a regulatory deadline. Summit Therapeutics' Biologics License Application for ivonescimab, based on the HARMONi trial results, carries an FDA goal date of November 14, 2026.1 That is a month away. Summit's verified filings show what the company has spent to reach it.2
Summit reported zero revenue in both FY2023 and FY2024.2 Its net loss was $614.9 million in FY2023, $221.3 million in FY2024 and $1,079.6 million in FY2025. That is roughly five times the FY2024 loss.2 Loss per share was $0.99 in FY2023, $0.31 in FY2024 and $1.44 in FY2025.2
Net loss and cash spent are different measures, and the gap between them is large here. Operating cash outflow was $76.8 million in FY2023, $142.1 million in FY2024 and $322.9 million in FY2025.2 FY2025's cash burn is about 2.3 times FY2024's. Operating loss was $609.7 million in FY2023 and $226.0 million in FY2024.2 The verified data we hold does not explain why FY2023's loss was so far above its cash outflow, so we do not guess at it. Likewise, the dossier holds an R&D expense figure only for FY2023, at $59.5 million.2 We cannot say how R&D spending split across the later years.
Capital spending on equipment and facilities is tiny next to those losses: $128,000 in FY2023, $139,000 in FY2024 and $657,000 in FY2025.2 The money is going out through the operating line, not into buildings or machinery. That fits a company with no product yet on the market.
A cash balance that moves in jumps
The cash line tells you how this kind of company lives. Summit held $71.4 million at the end of FY2023 and $104.9 million at the end of FY2024.2 Within those years, the quarterly figures swing widely. Cash was $61.3 million in Q1 2024, $28.4 million in Q2 2024 and $93.8 million in Q3 2024.2
The pattern repeats in 2025. Cash was $211.5 million in Q1, $297.9 million in Q2 and $238.6 million in Q3, then $225.3 million at fiscal year-end.2 In 2026 it was $106.5 million in Q1 and then $419.4 million in Q2.2
Cash that falls and then jumps in this way usually points to new money arriving. But the verified records we hold do not say where the Q2 2026 increase came from, so we are not going to assert it. What the numbers do show is that Summit has not run on a steady cushion. Its balance has repeatedly dropped low before rising again. For a shareholder, the practical question ahead of November 14 is how the company funds a launch, and the filings in our data do not answer it.
The same ledger, a different outcome
Not every company here is in pre-revenue mode. Novocure reported second-quarter 2026 net revenues of $184 million, up 16% year over year, with 18% growth in global active patients.3 It also reported a CE Mark for Optune Pax in locally advanced pancreatic cancer and more than 280 active patients on that product as of June 30, 2026.3 Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."3
Compare the two models. Summit is spending hundreds of millions on one regulatory outcome. Novocure is growing a marketed product line. Both sit under the label "oncology innovation," but the financial risk is very different.
Cost discipline is also part of the picture. ADC Therapeutics announced a workforce reduction that it said is "projected to deliver $10 million in annualised cost savings," and said it "maintains a cash runway into 2028."4 A smaller company can reasonably choose to shrink its cost base and stretch its funding, rather than raise capital.
Where the big money is going: care delivery
The largest dollar figure in the dossier concerns delivery, not discovery. On October 6, 2026, McKesson and Clayton, Dubilier & Rice announced a take-private acquisition of Option Care Health at $32.05 per share. That is a 37% premium to the previous closing price and values the company at $5.8 billion including debt. CD&R would own 51% and McKesson 49%.5
To picture the scale, $5.8 billion is about 14 times Summit's Q2 2026 cash balance of $419.4 million.2,5 We have no further detail in our data on how the deal is financed. We also cannot say whether ordinary index-fund holders own the company. The dossier does not give index weightings, and we will not invent one.
What we can say is what the structure suggests. Our reading is that buyers are willing to pay a premium for the services around drug administration, not just for the drugs. That is Via News's interpretation of a single deal, not an external finding. The dossier also points to behavioral-health tie-ins with oncology practices as part of a broader care model, but it holds no figures on them, so we leave that thread undeveloped.
Data milestones that move valuations
Several clinical readouts could change how the market values these companies. EXCALIBER-RRMM, a Phase 3 trial in relapsed or refractory multiple myeloma, reported topline progression-free survival (PFS) results on October 8, 2026. The ZDd regimen showed a median PFS of 42 months against 20 months for DVd (hazard ratio 0.49, p<0.000001), a 51% reduction in the risk of progression or death. Median follow-up was 23 months.6
One detail deserves care. The reported median PFS of 42 months is longer than the 23-month median follow-up. That can happen when many patients have not yet progressed, but it means the figure is an early estimate. Investors should wait for the full presentation before treating 42 months as settled.
Elsewhere, the FDA approved Tecentriq for adjuvant stage III dMMR colon cancer on October 9, 2026, its twelfth U.S. indication.7 Gilead's Trodelvy plus Keytruda received a positive CHMP opinion in first-line metastatic triple-negative breast cancer on July 24, 2026.8 Telix dosed the first patient in its Phase 3 LUTEON trial of TLX250-Tx on July 21, 2026.9 Next, Moderna and Merck plan to present detailed intismeran results at ESMO on October 24 and to engage regulators about possible filings.10
AI discovery: a promise, with an evidence problem
The third front is AI-designed medicine. In a piece in MIT Technology Review, Puja Sapra describes a "lab of the future." "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."11 She also argues that AstraZeneca's proprietary data is the edge: "Data is our differentiator."11
The same piece names the unsolved part: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."11 No financial result is attached to any of this in our dossier. Readers should treat it as a statement of strategy, not a measured payoff.
How much to trust each source
Our verification system measures how often claims from each source held up when checked. The MIT Technology Review piece scored 0% of 11 checked claims.11 The quotes above are verbatim, but that sample is small and the record is poor, so we present them as the company's stated aims.
Wire-style press releases were mixed. The Novocure and Gilead releases came from a source where 56% of 4,957 checked claims held up.3,8 The Telix release came from a source where 31% of 2,928 checked claims held up.9 The weekly biotech roundup carrying the ADC Therapeutics statements scored 46% of 520.4 By contrast, the Summit figures come from SEC filings and are marked verified.2 That is why they carry most of the weight in this piece.
What to watch
- October 24: detailed intismeran results at ESMO.10
- November 14: the FDA's decision date on ivonescimab.1
- Summit's next filing: whether the cash balance, which was $419.4 million in Q2 2026, holds up against an operating burn that was $322.9 million in FY2025.2
- Option Care Health: whether further take-privates follow in care delivery after a deal at a 37% premium.5
